The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Jonathan R Strosberg; Thorvardur R Halfdanarson; Andrew M Bellizzi; Jennifer A Chan; Joseph S Dillon; Anthony P Heaney; Pamela L Kunz; Thomas M O'Dorisio; Riad Salem; Eva Segelov; James R Howe; Rodney F Pommier; Kari Brendtro; Mohammad A Bashir; Simron Singh; Michael C Soulen; Laura Tang; Jerome S Zacks; James C Yao; Emily K Bergsland

doi:10.1097/MPA.0000000000000850

Back

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Journal article

Peer reviewed

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Jonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, Jennifer A Chan, Joseph S Dillon, Anthony P Heaney, Pamela L Kunz, Thomas M O'Dorisio, Riad Salem, Eva Segelov, …

Pancreas, Vol.46(6), pp.707-714

07/2017

DOI: 10.1097/MPA.0000000000000850

PMCID: PMC5642985

PMID: 28609356

View Online

Abstract

There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patients with refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

Predictive Value of Tests

Intestinal Neoplasms - mortality

Humans

Risk Factors

Treatment Outcome

Neuroendocrine Tumors - diagnosis

Consensus

Patient Selection

Evidence-Based Medicine - standards

Intestinal Neoplasms - therapy

Clinical Decision-Making

Neuroendocrine Tumors - mortality

Medical Oncology - standards

Neuroendocrine Tumors - therapy

Intestinal Neoplasms - diagnosis

Societies, Medical - standards

Details

Title: Subtitle: The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
Creators: Jonathan R Strosberg
Thorvardur R Halfdanarson
Andrew M Bellizzi
Jennifer A Chan
Joseph S Dillon
Anthony P Heaney
Pamela L Kunz
Thomas M O'Dorisio
Riad Salem
Eva Segelov
James R Howe
Rodney F Pommier
Kari Brendtro
Mohammad A Bashir
Simron Singh
Michael C Soulen
Laura Tang
Jerome S Zacks
James C Yao
Emily K Bergsland
Resource Type: Journal article
Publication Details: Pancreas, Vol.46(6), pp.707-714
DOI: 10.1097/MPA.0000000000000850
PMID: 28609356
PMCID: PMC5642985
NLM abbreviation: Pancreas
ISSN: 0885-3177
eISSN: 1536-4828
Publisher: United States
Grant note: P30 CA086862 / NCI NIH HHS P50 CA174521 / NCI NIH HHS
Language: English
Date published: 07/2017
Academic Unit: Pathology; Surgery; Fraternal Order of Eagles Diabetes Research Center; Cardiothoracic Surgery; Endocrinology and Metabolism; Internal Medicine
Record Identifier: 9984047637602771

Metrics

20 Record Views

244 Times Cited - Web of Science

See more details